Mode
Text Size
Log in / Sign up

Trazodone improves sleep architecture and duration in patients with depression and sleep disordersTrazodone may improve sleep quality for people with depression

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that trazodone improves sleep duration and SWS in depressed patients but increases somnolence and dizziness.

This exploratory meta-analysis synthesized data from 5 RCTs and 3 single-arm studies to evaluate the effects of trazodone on sleep parameters in patients with depression and sleep disorders. The analysis included a total sample size of 980 patients. The study focused on polysomnography-derived sleep stages and related metrics such as total sleep time and sleep efficiency.

Key findings indicate that trazodone is associated with increased total sleep time and increased sleep efficiency. Regarding sleep architecture, trazodone was associated with a reduction in non-rapid eye movement sleep stage 2 (N2) proportion (MD = -9.09; 95% CI -16.60 to -1.59, P = 0.017) and an increase in slow wave sleep (SWS) proportion (MD = 8.05; 95% CI 3.42 to 12.68, P = 0.001). No significant effects were observed for wake after sleep onset, NREM stage 1 percentage, REM sleep percentage, or REM sleep latency.

While trazodone may improve objective sleep continuity and architecture, the authors note that these benefits are associated with a higher rate of adverse events compared to placebo, specifically somnolence and dizziness. The study is characterized as an exploratory meta-analysis. Clinical application should consider the trade-off between improved sleep architecture and increased side effects.

How this fits prior evidence

This finding addresses a gap in the management of comorbid depression and sleep disorders. While prior evidence notes that sedating antidepressants vary in antidepressant activity and side effects, this meta-analysis specifically quantifies the impact of trazodone on sleep architecture, showing increased SWS and reduced N2. It provides specific data on sleep metrics that differ from the general observation that DORAs have the strongest evidence for insomnia.

Living with depression often comes with a heavy burden of poor sleep. It can be hard to fall asleep or stay asleep, making it even harder to manage daily life. Researchers looked at how the medication trazodone affects sleep patterns in patients dealing with both depression and sleep disorders.

In a review of several studies involving 980 patients, the data showed that trazodone helped people fall asleep faster and stay asleep longer. It also improved sleep efficiency, which is a measure of how much time spent in bed is spent actually sleeping. Specifically, the medication was linked to an increase in slow wave sleep, which is a deep stage of sleep, and a decrease in a lighter stage of sleep.

While these changes in sleep structure were observed, the medication did not significantly change REM sleep. However, these benefits come with trade-offs. Patients taking trazodone reported more side effects than those taking a placebo, particularly feeling dizzy or excessively sleepy. Because this was an exploratory analysis, these findings show a promising link but require careful consideration of the side effects.

What this means for you:
Trazodone can improve sleep duration and quality for those with depression, but it may cause dizziness and sleepiness.

Common questions

How does trazodone affect sleep for people with depression?

Trazodone can help patients with depression fall asleep faster and increase their total sleep time. It also improves sleep efficiency and increases the amount of slow wave sleep, which is a deep stage of sleep. However, it does not significantly change REM sleep or the time it takes to reach REM sleep.

What are the side effects of taking trazodone?

People taking trazodone may experience more side effects than those taking a placebo. The most common issues reported include somnolence, which is extreme sleepiness, and dizziness. These side effects must be weighed against the improvements in sleep quality.

Is trazodone effective for different types of sleep?

The data shows trazodone increases slow wave sleep and decreases the proportion of stage 2 sleep. It does not have a significant effect on REM sleep or the amount of time spent awake after falling asleep. Talk to your doctor to see if this medication fits your specific needs.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
ObjectiveSleep disturbance and cognitive impairment are common in depression. Trazodone is often used for sleep problems and may improve cognition by modifying sleep architecture. However, its effects on specific polysomnography-derived sleep stages remain unclear. This systematic review and exploratory meta-analysis aimed to investigate trazodone’s effects on sleep architecture in patients with depression and sleep disorders.MethodsSeven databases were searched for interventional studies published up to October 2025. Random-effects models were applied to estimate pooled mean differences (MDs) and risk ratios (RRs), as appropriate.ResultsEight studies involving 980 patients were included: five randomized controlled trials and three single-arm studies. Compared with baseline, trazodone was associated with increased total sleep time and sleep efficiency, and with reduced sleep latency. Regarding sleep architecture, trazodone was linked to reduced non-rapid eye movement sleep stage 2 (N2) proportion (MD = −9.09, 95% CI −16.60 to −1.59, P = 0.017) and increased slow wave sleep (SWS) proportion (MD = 8.05, 95% CI 3.42 to 12.68, P = 0.001). No significant effects were observed for wake after sleep onset, NREM stage 1 percentage, rapid eye movement sleep percentage (REM), and REM sleep latency. Secondary outcomes suggested reduced HAMD-17 scores and higher response rates versus placebo, but more adverse events, especially somnolence and dizziness, with trazodone.ConclusionTrazodone may improve objective sleep continuity and may be associated with changes in sleep architecture, including increased SWS and reduced N2 sleep, in patients with depression, without significantly altering REM sleep. These potential benefits should be weighed against increased adverse events.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251173354.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.